These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21294702)

  • 21. Dementia with cerebrovascular disease: the benefits of early treatment.
    Schindler RJ
    Eur J Neurol; 2005 Oct; 12 Suppl 3():17-21. PubMed ID: 16144533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.
    McGuinness B; Todd S; Passmore P; Bullock R
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004034. PubMed ID: 16625595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of vascular cognitive impairment and dementia.
    Erkinjuntti T
    J Neural Transm Suppl; 2002; (63):91-109. PubMed ID: 12597611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How Treatable is Vascular Dementia?].
    Mori E
    Brain Nerve; 2016 Apr; 68(4):441-50. PubMed ID: 27056862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.
    Rojas-Fernandez CH; Moorhouse P
    Ann Pharmacother; 2009 Jul; 43(7):1310-23. PubMed ID: 19584390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.
    Passmore AP; Bayer AJ; Steinhagen-Thiessen E
    J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigational treatment for vascular cognitive impairment.
    Birks J; Flicker L
    Expert Opin Investig Drugs; 2007 May; 16(5):647-58. PubMed ID: 17461738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
    Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
    Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review.
    Shah K; Qureshi SU; Johnson M; Parikh N; Schulz PE; Kunik ME
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):250-61. PubMed ID: 19948301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed dementia: emerging concepts and therapeutic implications.
    Langa KM; Foster NL; Larson EB
    JAMA; 2004 Dec; 292(23):2901-8. PubMed ID: 15598922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular dementia: prevention and treatment.
    McVeigh C; Passmore P
    Clin Interv Aging; 2006; 1(3):229-35. PubMed ID: 18046875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.
    Rouch L; Cestac P; Hanon O; Cool C; Helmer C; Bouhanick B; Chamontin B; Dartigues JF; Vellas B; Andrieu S
    CNS Drugs; 2015 Feb; 29(2):113-30. PubMed ID: 25700645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic dysfunction in vascular dementia.
    Román GC
    Curr Psychiatry Rep; 2005 Mar; 7(1):18-26. PubMed ID: 15717981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholinesterase inhibitors: drugs looking for a disease?
    Maggini M; Vanacore N; Raschetti R
    PLoS Med; 2006 Apr; 3(4):e140. PubMed ID: 16597173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
    Li Y; Hai S; Zhou Y; Dong BR
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
    Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
    Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular dementia may be the most common form of dementia in the elderly.
    Román GC
    J Neurol Sci; 2002 Nov; 203-204():7-10. PubMed ID: 12417349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.